IRIS
GEBBIA, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.056
NA - Nord America 1.773
EU - Europa 1.679
SA - Sud America 526
AF - Africa 22
Totale 6.056
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.719
IE - Irlanda 1.057
SG - Singapore 970
HK - Hong Kong 826
BR - Brasile 491
DE - Germania 137
IT - Italia 127
GB - Regno Unito 118
TR - Turchia 77
CN - Cina 59
FR - Francia 51
FI - Finlandia 38
CH - Svizzera 37
CA - Canada 29
IN - India 23
NL - Olanda 21
BD - Bangladesh 20
MX - Messico 20
RU - Federazione Russa 18
AR - Argentina 14
CZ - Repubblica Ceca 14
AT - Austria 12
IQ - Iraq 11
JP - Giappone 10
SE - Svezia 9
MA - Marocco 8
UA - Ucraina 8
ZA - Sudafrica 8
PL - Polonia 7
UZ - Uzbekistan 7
VN - Vietnam 7
KR - Corea 6
AL - Albania 5
EC - Ecuador 5
AZ - Azerbaigian 4
BO - Bolivia 4
IL - Israele 4
LT - Lituania 4
PK - Pakistan 4
VE - Venezuela 4
BE - Belgio 3
ES - Italia 3
KZ - Kazakistan 3
LB - Libano 3
NP - Nepal 3
PY - Paraguay 3
SA - Arabia Saudita 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
IR - Iran 2
JO - Giordania 2
LV - Lettonia 2
PH - Filippine 2
RO - Romania 2
UY - Uruguay 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GR - Grecia 1
HN - Honduras 1
ID - Indonesia 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TM - Turkmenistan 1
TW - Taiwan 1
Totale 6.056
Salva come PNG Salva come JPEG
Città #
Dublin 1.051
Hong Kong 823
Boardman 375
Singapore 360
Santa Clara 314
The Dalles 266
Ashburn 106
London 96
Istanbul 69
Zurich 37
Helsinki 36
São Paulo 36
Los Angeles 35
Assago 32
Chicago 31
Munich 30
Prineville 26
Fort Worth 24
Milan 24
Chandler 23
Frankfurt am Main 20
Belo Horizonte 19
Springfield 17
Rio de Janeiro 15
Amsterdam 14
Brooklyn 13
Boston 12
Washington 12
Ottawa 11
San Francisco 11
New York 10
Phoenix 10
Tokyo 10
Berlin 9
Brasília 9
Brno 9
Montreal 9
Catania 8
Charlotte 8
Curitiba 8
Düsseldorf 8
Mexico City 8
Naples 8
Seattle 8
Shanghai 8
Johannesburg 7
New Delhi 7
Nuremberg 7
Porto Alegre 7
Tashkent 7
Atlanta 6
Dallas 6
Goiânia 6
Lauterbourg 6
Misilmeri 6
Rome 6
Warsaw 6
Caxias do Sul 5
Moscow 5
Olomouc 5
Princeton 5
Seoul 5
Vienna 5
Volta Redonda 5
Baghdad 4
Baku 4
Betim 4
Campinas 4
Campo Grande 4
Guangzhou 4
Guarulhos 4
Guayaquil 4
Ho Chi Minh City 4
Itaquaquecetuba 4
Juiz de Fora 4
Modena 4
Piracicaba 4
Portsmouth 4
Tirana 4
Vila Velha 4
West Jordan 4
Aparecida de Goiânia 3
Belém 3
Brussels 3
Buffalo 3
Caruaru 3
Cedar Knolls 3
Chennai 3
Denver 3
Dhaka 3
Erbil 3
Itajaí 3
Manaus 3
Maringá 3
Palermo 3
Palhoça 3
Patos de Minas 3
Philadelphia 3
Piscataway 3
Praia Grande 3
Totale 4.305
Salva come PNG Salva come JPEG
Nome #
112. UN NUOVO INDICE PROGNOSTICO-TERAPEUTICO IN ONCOLOGIA GERIATRICA 245
Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma? 76
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis 66
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 64
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 62
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated? 59
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 55
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer 54
Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients' Queries, Needs, Fears, and Actions Taken 54
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 54
Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report 52
Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis 51
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: A whatsapp messenger-based report from the Italian college of chief medical oncologists 51
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 50
A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy 50
Gastric metastasis from breast cancer 46
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer 46
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients 43
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 39
Safety of a 3-weekly schedule of carboplatin pegylate liposomal doxorubicin as first line chemotherapy results in patients with ovarian cancer preliminary results of the MITO-2 randomized trial 38
null 37
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 37
[First line chemotherapy in non-small cell lung carcinoma: a solved dilemma] 36
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 35
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 34
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. 34
A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine 34
Combined Neuroendocrine Carcinoma and Hepatocellular Carcinoma of the Liver: Systematic Literature Review Suggests Implementing Biological Characterization to Optimize Therapeutic Strategy 33
Non-palpable Pulmonary Nodules and Uniportal-VATS: Radio-guided Localization (ROLL) Experience of a Lung Multidisciplinary Team 33
Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient 32
Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice 31
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group 31
null 29
Toward a New Prognostic-Therapeutic Index in Geriatric Oncology 29
A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study 28
The Effects of the Macrocyclic Lactone Bryostatin-1 on Leukemic Cells in Vitro 28
null 28
Relationship of Inflammatory Parameters and Nutritional Status in Cancer Patients 27
New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful? 27
Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: A case report 27
null 27
5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group 26
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium 26
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale 26
Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma 26
null 26
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial 26
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial 25
In vivo stimulation of murine haematopoiesis by the antineoplastic agent bryostatin-1 25
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study 25
The impact of anemia on quality of life and hospitalisation in elderly cancer patients undergoing chemotherapy 25
Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen 25
Brain Metastasis in Endometrial Cancer: A Systematic Review 24
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA) 24
First-line treatment with epirubicin and vinorelbine in metastatic breast cancer 24
Nutritional management of the patient with pancreatic cancer: From the diagnostic and therapeutic pathway to an integrated hospital-territory approach 24
A Phase I—II Study of Cyclophosphamide, Epidoxorubicin, Levofolinic Acid/5-Fluorouracil and Recombinant Human Granulocyte Colony Stimulating Factor in Metastatic Breast Carcinoma 24
Abemaciclib in Patients with End-Stage Renal Disease and Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Report of 2 Cases 24
Radiofrequency Thermoablation and Hypofractionated Radiotherapy Combined Treatment for Bone Metastases: A Retrospective Study 24
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society of Medical Oncology (AIOM) 23
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial 23
Subcutaneous recombinant-human-erythropoietin prevents chemotherapy-related anemia in patients with advanced cancer 23
Neo-adjuvant organ-preserving chemotherapy in the management of locally advanced oral cavity and oropharynx cancer 23
Cetuximab in squamous cell head and neck carcinomas 23
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study 23
TOWARD A NEW PROGNOSTIC-THERAPEUTIC INDEX IN GERIATRIC ONCOLOGY 23
Liability of clinical oncologists and the COVID-19 emergency: Between hopes and concerns 23
Chemotherapy in Head and Neck Cancer (I): Management of Recurrent or Metastatic Disease 22
Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer 22
Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial 22
Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE) 22
New opioids. 22
Cancer: New needs, new models. is it time for a community oncologist? another brick in the wall 22
Combination Chemotherapy with Cyclophosphamide, Doxorubicin and Vincristine in the Treatment of Stage III-IV Small-Cell Lung Cancer 22
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 22
5-Fluorouracil and Recombinant Alpha Interferon-2a in the Treatment of Advanced Colorectal Carcinoma: a Dose Optimization Study 22
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer 22
Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy:a multicenter phase III study 22
The in vitro effect of the antineoplastic agent bryostatin 4 on human hematopoietic progenitor cells 22
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin plus etoposide in extensive small-cell lung cancer (SCLC) patients The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial 22
Virtual clinical and precision medicine tumor boards-cloud-based platform-mediated implementation of multidisciplinary reviews among oncology centers in the covid-19 era: Protocol for an observational study 21
Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience 21
Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the gruppo oncologico italia meridionale 21
Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report 21
Soluble interleukin-2 receptor in vitro production by mononuclear cells from Hodgkin patients 21
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study 21
A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group 21
Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group 21
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme 21
Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer? 20
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas 20
Evolution of Therapy Decision-Making Process for Advanced Non-Small Cell Lung Cancer 20
A Phase II Study of Levofolinic Acid and 5-Fluorouracil Plus Cisplatin in Patients with Advanced Head and Neck Squamous Cell Carcinoma 20
The Consistency and Quality of ChatGPT Responses Compared to Clinical Guidelines for Ovarian Cancer: A Delphi Approach 20
Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer 20
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma 20
The Effectiveness of Combination Chemotherapy with Cisplatinum and Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer 20
5-fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: Results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.) 20
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale 20
Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells 20
Totale 3.240
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.241
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.241
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202226 0 0 0 0 0 0 0 5 2 7 2 10
2022/2023174 13 14 4 8 6 13 3 12 8 3 49 41
2023/2024970 39 84 66 77 138 104 158 62 50 52 40 100
2024/20255.230 423 366 528 100 512 470 409 278 757 561 565 261
Totale 6.400